Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Finger-Prick test may predict sepsis severity

NCT ID NCT02180399

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether measuring lactate from a finger-prick (capillary blood) can help doctors identify sepsis patients who need intensive care. Researchers enrolled 60 adults with signs of sepsis outside the ICU. The goal was to see if this quick, bedside test could catch early metabolic problems better than standard blood tests, potentially guiding treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a faster, simpler way to spot which sepsis patients need intensive care, potentially improving outcomes.
What could go wrong
This is a small, completed study with only 60 participants, so results may not apply widely. The test's accuracy in real-world settings is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Feb 2014

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients over age 18 with an acute systemic inflammatory response syndrome array of presumed infectious not yet been treated.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Installation without any plausible explanation of at least one of the following clinical criteria: * Chills, fever, mottling, respiratory rate\> 20/min; Sat02 \< 90% or \> 94% with more than 4l O2, heart rate \> 90/min,systolic blood pressure \< 100 mmHg or 40 mmHg lower compared with normal values, Glasgow coma score \< 14. or: .a combination of two (or more) of clinical and laboratory criteria for sepsis. * Signed informed consent form Exclusion Criteria: * Need in its current treatment of aerosol administration of beta agonists at a frequency greater than one per 8 hours; * Targeted therapeutic measures have already stated for more than 60 minutes; * Diagnosis other than Sepsis; * Malignant neoplasm or other progressive disease and expected survival was less than 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis

Contacts and locations

Locations

  • SERVICE DE MED. INTERNE - DIABETE ET MALADIES METABOLIQUES, 1-place de l'Hôpital

    Strasbourg, 67091, France

  • Service de Médecine Interne - Clinique Médicale B

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.